FDA Approves Regeneron’s Pasatru for Rare Bone Disorder FOP
Regeneron Pharmaceuticals has received U.S. Food and Drug Administration approval for Pasatru (garetosmab-grts), a new treatment for adults living with fibrodysplasia ossificans…
Read More...
Read More...
